From fungus to pharmaceuticals - the chemistry of statins

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 12, 2012, Pages 1250-1260

  McPherson, P A C ^a  

^a Belfast Metropolitan College   (United Kingdom)

Author keywords

Cardiovascular disease; Cholesterol; HMG CoA reductase; Hypercholesterolaemia; Lipoproteins

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; 7 [4 (4 FLUOROPHENYL) 6 ISOPROPYL 2 [METHYL(1 METHYL 1H 1,2,4 TRIAZOL 5 YL)AMINO] 5 PYRIMIDINYL] 3,5 DIHYDROXY 6 HEPTENOIC ACID; AMINO ACID; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; COMPACTIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB; TRIPARANOL; VERY LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR DISEASE; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; COMPETITIVE INHIBITION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG INDUSTRY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSLIPIDEMIA; FIRST PASS EFFECT; FUNGUS; HUMAN; HYDROGEN BOND; HYPERCHOLESTEROLEMIA; LIVER TOXICITY; MOLECULAR INTERACTION; MYOPATHY; NONHUMAN; ONE POT SYNTHESIS; PHARMACOPHORE; REVIEW; RHABDOMYOLYSIS; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL; FUNGI; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84866439164     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712802762103     Document Type: Review

References (66)

1. Mihos, C.G.; Salas, M.J.; Santana, O. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review. Cardiol Rev., 2010, 18, 298-304.
2. Toth, P.P. Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs. Drugs, 2010, 70, 1363-1379.
3. Kostapanos, M.S.; Milionis, H.J.; Elisaf, M.S. Current role of statins in the treatment of essential hypertension. Expert Opin. Pharmacother., 2010, 11, 2635-2650.
4. Steinberg, D. Thematic review series: The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part I. J. Lipid Res., 2004, 45, 1583-1593.
5. Gordon, T.; Casstelli, W.P.; Hjortland, M.C.; Kannel, W.B.; Dawber, T.R. High density lipoprotein as a protective factor against coronary heart disease: The Framingham study. American Journal of Medicine, 1977, 62, 704-714.
6. Ravnskov, U. Dietary fat is not the villain. BMJ, 2005, 331, 906-907.
7. Olson, R.E. Discovery of the lipoproteins, their role in fat transport and their significance as risk factors. J. Nutr., 1998, 128, 439S-443S.
8. Vance D.E.; van den Bosch, H. Cholesterol in the year 2000. Biochim. Biophys. Acta., 2000, 1529,1-8.
9. Bloch, K. Sterol molecule: structure, biosynthesis, and function. Steroids, 1992, 57, 378-383.
10. Tabas, I. Cholesterol in health and disease. J. Clin. Invest., 2002, 110, 583-590.
11. Fernandez, M.L.; West, K.L. Mechanisms by which dietary fatty acids module plasma lipids. J. Nutr. 2005, 135, 2075-2078.
12. Young, I.S. Lipids for psychiatrists-an overview. J. Psychopharmacol., 1995, 19, 66-75.
13. Mahley, R.W.; Innerarity, T.T.; Rall, S.C.; Weisgraber, K.H. Plasma lipoproteins: apolipoprotein structure and function. J. Lipid Res., 1984, 25, 1277-1294.
14. Russell, D.W.; Setchell, K.D. Bile acid biosynthesis. Biochemistry, 1992, 31, 4737-4749.
15. Jessup W.; Kritharides, L.; Stocker, R. Lipid oxidation in atherogenesis: an overview. Biochem. Soc. Trans., 2004, 32, 134-138.
16. Brown M.S.; Goldstein, J.L. A receptor-mediated pathway for cholesterol homeostasis. Science, 1986, 232, 34-47.
17. Fielding C.J.; Fielding, P.E. Molecular physiology of reverse cholesterol transport. J. Lipid Res., 1995, 36, 211-228.
18. Barter P.J.; Kastelein, J.J. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J. Am. Coll. Cardiol., 2006, 47, 492-499.
19. 4-cholestenone in animals and in man. Proc. Soc. Exp. Biol., 1958, 98, 784-790.
20. Steinberg, D.; Avigan, J.; Feigelson, E.B. Effects of Triparanol (Mer-29) on cholesterol biosynthesis and on blood sterol levels in man. J. Clin. Invest., 1961, 40, 884-893.
21. Tanzawa, K.; Kuroda, M.; Endo, A. Time-dependent, irreversible inhibition of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase by the antibiotic citrinin. Biochem. Biophys. Acta., 1977, 488, 97-101.
22. Endo, A. Compactin (ML-236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductase. J. Med. Chem., 1985, 28, 401-405.
23. Robertson, J.G. Mechanistic basis of enzyme-targeted drugs. Biochemistry, 2005, 44, 5561-5571.
24. Shigematsu, H.; Hata, Y.; Yamamoto, M.; Oikawa, T.; Yamauchi, Y.; Nakaya, N.; Goto, Y. Treatment of hypercholesterolemia with an HMG-CoA reductase inhibitor (CS-500). Phase I study in normal subjects. Geriat. Med. (Japan), 1979, 17, 1564-1573.
25. Grundy, S.M. HMG-CoA reductase inhibitors for the treatment of hypercholesterolema. N. Engl. J. Med., 1988, 319, 24-33.
26. Endo, A. The origin of the statins. International Congress Series, 2004, 1262, 3-8.
27. Corsini, A.; Maggi, F.M.; Catapano, A.L. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol. Res., 1995, 31, 9-27.
28. Radulovic, L.L.; Cilla, D.D.; Posvar, E.L.; Sedman, A.J.; Whitfield, L.R. Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. J. Clin. Pharmacol., 1995, 35, 990-994.
29. Taillon, M.; Côté, C.; Furtado, M.; Garofolo, F. Potentially new isobaric metabolite of fluvastatin observed by LC-MS/MS during incurred sample analysis. Bioanalysis, 2011, 3, 1827-1835.
30. Davidson, M.H. Fluvastatin long-term extension trial (FLUENT): Summary of efficacy and safety. Am. J. Med., 1994, 96, 41.
31. Hamelin, B.A.; Turgeoun, J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends in Pharmacological Sciences, 1998, 19, 36-37
32. Ho, R.H.; Tirona, R.G.; Leake, B.F.; Glaeser, H.; Lee, W.; Lemke, C.J. Wang, Y.; Kim, R.B. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology, 2006, 130, 1793-1806.
33. Bottorff, M.; Hansten, P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians. Arch. Intern. Med., 2000, 160, 2273-2280.
34. Tse, F.L.; Jaffe, J.M.; Troendle, A.; Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J. Clin. Pharmacol., 1992, 32, 630-638.
35. Schachter, M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fund. Clin. Pharm., 2004, 19, 117-125.
36. Boberg, M.; Angerbauer, R.; Fey, P.; Kanhai, W.K.; Karl, W.; Kern, A.; Ploschke, J.; Radtke, M. Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Drug Metab. Dispos., 1997, 25, 321-331.
37. Sidaway, J.; Davidson, R.; McTaggart, F. Effect of statins on protein uptake and cholesterol biosynthesis in kidney proximal tubule cells. Toxicol. Lett., 2003, 144, S96.
38. Black, D.M. A general assessment of the safety of HMG CoA reducase inhibitors (statins). Curr. Atherosclero. Rep., 2002, 4, 34-41.
39. Staffa, J.A.; Chang, J.; Green, J. Cervistatin and reports of fatal rhabdomyolysis. N. Eng. J. Med., 2002, 346, 539-540.
40. Ballantyre, C.M.; Corsini, A.; Davidson, M.H.; Holdaas, H.; Jacobson, T.A.; Leitersdorf, E.; März, W.; Reckless, J.P.; Stein, E.A. Risk for myopathy with statin therapy in high-risk patients. Arch. Intern. Med., 2003, 163, 553-564.
41. Jacobson, T.A. Statin safety: lessons from new drug applications for marketed statins. Am. J. Cardiol., 2006, 97, 44C-51C.
42. Istvan, E.S.; Palnitkar, M.; Buchanan, S.K.; Deisenhofer, J. Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis. EMBO J., 2000, 19, 849-860.
43. Istvan, E.S.; Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science, 2001, 292, 1160-1164.
44. Straathof, A.J.J.; Panke, S.; Schmid, A. The production of fine chemicals by biotransformations. Current Opinion in Biotechnology, 2002, 13, 548-556.
45. Vederas, J.C.; Moore, R.N.; Bigam, G.; Chan, K.J. Biosynthesis of the hypocholesterolemic agent mevinolin by Aspergillus terreus. Determination of the origin of carbon, hydrogen and oxygen by 13C NMR and mass spectrometry. J. Am. Chem. Soc., 1985, 107, 3694-3701.
46. Hoffman, W.F.; Alberts, A.W.; Anderson, P.S.; Chen, J.S.; Smith, R.L.; Willard, A.K. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin. J. Med. Chem., 1986, 29, 849-852.
47. Manzoni, M.; Rollini, M. Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs. Appl. Microbiol. Biotechnol., 2002, 58, 555-564.
48. Witter, D.J.; Vederas, J.C. Putative Diels-Alder catalyzed cyclization during the biosynthesis of lovastatin. J. Org. Chem., 1996, 61, 2613-2623.
49. Repič, O.; Prasad, K.; Lee, G.T. The story of lescol: from research to production. Org. Process Res. Dev., 2001, 5, 519-27.
50. Fuenfschilling, P.C.; Hoehn, P.; Mutz, J. An improved manufacturing process for fluvastatin. Org. Process Res. Dev., 2007, 11, 13-18.
51. Casar, Z. Straightforward and Efficient Synthesis of (4R,6S)-4- (tert-Butyldimethylsiloxy)-6-(hydroxymethyl) tetrahydropyran-2-one. Synlett, 2008, 2036-2040.
52. Casar, Z.; Steinbücher, M.; Košmrlj, J. Lactone pathway to statins utilizing the Wittig reaction. The synthesis of rosuvastatin. J. Org. Chem., 2010, 75, 6681-6684.
53. Richard, J.F; Christopher, D.; Mundorff, E.C.; Newman, L.M. Gavrilovic, V.; Ma, S.K. Chung, C.; Tam, S. Muley, S. Improving catalytic function by ProSAR driven enzyme evolution. Nature Biotechnol., 2007, 25, 338-44.
54. Brower, P.L.; Butler, D.E.; Deering, C.F.; Le, T.V.; Millar, A.; Nanninga, T.N.; Palmer, C.W.; Roth, B.D. The convergent synthesis of (4R-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate, a key intermediate for the preparation of CI-981, a highly potent, tissue selective inhibitor of HMG-CoA reductase. Tetrahedron Lett., 1995, 33, 2279-2282.
55. Takemoto, M.; Liao, J.K. Pleiotropic effects of 3-hydroxy-3- methylglutarylcoenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 1712-1719.
56. Aviram M.; Rosenblat, M.; Bisgaier, C.L.; Newton, R.S. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis, 1998, 138, 271-280.
57. Davignon, J.; Jacob, R.F.; Mason, R.P. The antioxidant effect of statins. Coronary Artery Disease, 2004, 15, 251-258.
58. Hobson, L.A.; Akiti, O.; Deshmukh, S.S.; Harper, S.; Katipally, K.; Lai, C.J.; Livingston, R.C.; Lo, E.; Miller, M.M.; Ramakrishnan, S.; Shen, L.; Spink, J.; Tummala, S.; Wei, C.; Yamamoto, K.; Young, J.; Parsons, R.L. Development of a scalable process for the synthesis of a next-generation statin. Org. Process Res. Dev., 2010, 14, 441-458.
59. Zhang, Q.Y.; Wan, J.; Xu, X.; Yang, G.F.; Ren, Y.L.; Liu, J.J.; Wang, H.; Guo, Y. Structure-based rational quest for potential novel inhibitors of human HMG-CoA reductase by combining CoMFA 3D QSAR modelling and virtual screening. Journal of Combinatorial Chemistry, 2006, 9, 131-138.
60. Barter, P. CETP and atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2029-2031.
61. Tall, A.R.; Yvan-Charvet, L.; Wang, N. The failure of torecetrapib. Was it the molecule or the mechanism? Arterioscler. Thromb. Vasc. Biol., 2007, 27, 257-260.
62. Cannon, C.P.; Shah, S.; Dansky, H.M.; Davidson, M.D.; Brinton, E.A.; Gotto, A.M.; Stepanavage, M.; Liu, S.X.; Gibbons, P.; Ashraf, T.B.; Zafarino, J.; Mitchel, Y. Barter, P. Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. N. Engl. J. Med., 2010, 363, 2406-2415.
63. Rosenson, R.S. Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia. Expert Rev. Cardiovasc. Ther., 2003, 1, 495-505.
64. Olsson, A.G.; Pears, J.; McKellar, J.; Mizan, J.; Raza, A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am. J. Cardiol., 2001, 88, 504-508.
65. Saito Y.; Yamada N.; Teramoto T.A. Randomized double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesteremia. Atherosclerosis, 2002, 162, 373-379.
66. Black D.M. A general assessment of the safety of HMG CoA reductase inhibitors (statins). Curr. Atheroscler. Rep., 2002, 4, 34-41.